2000年到2012年FDA批准药物的靶点分析
本帖最后由 dejunchem 于 2013-6-19 19:38 编辑Abstract Pharmaceutical innovation is often measured by counting the new drugs approved by regulators. It is a simple and useful metric, but it has shortcomings. One of them is that it says little about the drugs’ innovativeness. Are they variations of older medicines, or molecules targeting entirely novel modes of action? As prices escalate, and payers and patients demand value, we need a better picture. This paper tries to provide it by analyzing the drugs approved by the U.S. FDA between 2000 and 2012. It examines their modes of action, highlights key trends and discusses their implications for our ability to generate innovation.
本帖最后由 dejunchem 于 2013-6-19 21:34 编辑
test 不错。了解下 很好的东西给力
页:
[1]